Prospera Private Wealth LLC Buys Shares of 1,049 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Prospera Private Wealth LLC purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 1,049 shares of the company’s stock, valued at approximately $42,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Great Point Partners LLC acquired a new position in Ionis Pharmaceuticals during the second quarter worth about $15,728,000. International Assets Investment Management LLC increased its stake in shares of Ionis Pharmaceuticals by 3,287.0% during the 3rd quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock worth $13,171,000 after purchasing an additional 319,065 shares in the last quarter. Logos Global Management LP purchased a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $14,298,000. Zimmer Partners LP acquired a new stake in Ionis Pharmaceuticals during the 1st quarter valued at $11,718,000. Finally, Marshall Wace LLP increased its position in Ionis Pharmaceuticals by 1,021.5% during the second quarter. Marshall Wace LLP now owns 173,199 shares of the company’s stock worth $8,255,000 after buying an additional 157,756 shares in the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the transaction, the chief executive officer now owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares of the company’s stock, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,197 shares of company stock worth $315,310. 2.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays increased their price objective on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Guggenheim lowered their price target on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Piper Sandler reduced their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. BMO Capital Markets cut shares of Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $67.00 to $60.00 in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.65.

Ionis Pharmaceuticals Trading Up 0.2 %

Shares of IONS stock opened at $34.01 on Friday. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $33.33 and a fifty-two week high of $54.44. The firm’s 50 day moving average price is $38.87 and its two-hundred day moving average price is $42.52. The stock has a market cap of $5.37 billion, a price-to-earnings ratio of -13.94 and a beta of 0.39. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.